Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brexpiprazole

FDA-approved product (tablet, oral), marketed as Brexpiprazole, Rexulti.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brexpiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brexpiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brexpiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

    NCT04124614 · start 2019-10-17

    Registered record
    Registry ID
    NCT04124614
    Conditions
    Post Traumatic Stress Disorder
    Interventions
    Brexpiprazole; Sertraline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-17
    Completion
    2023-08-08
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder
    InterventionBrexpiprazole; Sertraline; Placebo
    PhasePhase 3
    Registry statusCompleted

  • "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"

    NCT04641780 · start 2019-08-17

    Registered record
    Registry ID
    NCT04641780
    Conditions
    Schizophrenia; Major Depressive Disorder
    Interventions
    Brexpiprazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-08-17
    Completion
    2024-03
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Major Depressive Disorder
    InterventionBrexpiprazole
    PhaseNot recorded
    Registry statusUnknown

  • The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects

    NCT03734302 · start 2019-04-24

    Registered record
    Registry ID
    NCT03734302
    Conditions
    Healthy
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-24
    Completion
    2020-06-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBrexpiprazole
    PhasePhase 1
    Registry statusCompleted

  • A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

    NCT03594123 · start 2018-10-11

    Registered record
    Registry ID
    NCT03594123
    Conditions
    Alzheimer's Disease
    Interventions
    Brexpiprazole; Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-11
    Completion
    2022-09-19
    Enrolment
    259

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionBrexpiprazole; Brexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

    NCT03737474 · start 2018-10-04

    Registered record
    Registry ID
    NCT03737474
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-04
    Completion
    2021-04-13
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • A Study of Brexpiprazole in Patients With Major Depressive Disorder

    NCT03697603 · start 2018-07-30

    Registered record
    Registry ID
    NCT03697603
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-07-30
    Completion
    2022-07-04
    Enrolment
    740

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

    NCT03538691 · start 2018-07-13

    Registered record
    Registry ID
    NCT03538691
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole; Antidepressant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2022-07-29
    Enrolment
    1,149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole; Antidepressant therapy
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    NCT03557931 · start 2018-07-13

    Registered record
    Registry ID
    NCT03557931
    Conditions
    Schizophrenia
    Interventions
    ASP4345; placebo; risperidone; quetiapine; olanzapine; ziprasidone; aripiprazole; brexpiprazole; paliperidone; lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2019-10-21
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionASP4345; placebo; risperidone; quetiapine +6 more
    PhasePhase 2
    Registry statusCompleted

  • The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

    NCT03487198 · start 2018-05-30

    Registered record
    Registry ID
    NCT03487198
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-05-30
    Completion
    2019-05-30
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

    NCT03287869 · start 2017-10-24

    Registered record
    Registry ID
    NCT03287869
    Conditions
    Bipolar I Disorder; Acute Mania
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-24
    Completion
    2019-07-31
    Enrolment
    381

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Acute Mania
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

    NCT03292848 · start 2017-10-10

    Registered record
    Registry ID
    NCT03292848
    Conditions
    ADHD; Autism; Bipolar I Disorder; Conduct Disorder; Oppositional Defiant Disorder
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-10
    Completion
    2018-05-21
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionADHD; Autism; Bipolar I Disorder; Conduct Disorder +1 more
    InterventionBrexpiprazole
    PhasePhase 1
    Registry statusCompleted

  • A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

    NCT03259555 · start 2017-09-14

    Registered record
    Registry ID
    NCT03259555
    Conditions
    Bipolar I Disorder; Manic Episode
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-14
    Completion
    2019-01-02
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Manic Episode
    InterventionBrexpiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

    NCT03238326 · start 2017-08-23

    Registered record
    Registry ID
    NCT03238326
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-08-23
    Completion
    2025-04-22
    Enrolment
    295

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

    NCT03198078 · start 2017-06-30

    Registered record
    Registry ID
    NCT03198078
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole (OPC-34712); Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-30
    Completion
    2023-04-03
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole (OPC-34712); Aripiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

    NCT02758067 · start 2016-06

    Registered record
    Registry ID
    NCT02758067
    Conditions
    Schizophrenia
    Interventions
    brexpiprazole; risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-06
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionbrexpiprazole; risperidone
    PhasePhase 3
    Registry statusWithdrawn